Efficacy results subgroup analysis
| DLBCL type . | n . | ORR (%, 95% CI) . | CR (%, 95% CI) . | DCR (%, 95% CI) . | mPFS (weeks, 95% CI) . | 6-mo PFS (%, 95% CI) . | 12-mo PFS (%, 95% CI) . | mDOR (weeks, 95% CI) . |
|---|---|---|---|---|---|---|---|---|
| All DLBCL | 96 | 28 (19-38) | 9 (4-17) | 30 (21-40) | 9 (7-14) | 25 (17-35) | 15 (8-23) | 31 (18-73) |
| De novo DLBCL | 84 | 29 (19-40) | 11 (5-19) | 31 (21-42) | 8 (6-14) | 28 (19-37) | 17 (9-27) | 33 (20-NA) |
| Transformed lymphoma | 12 | 25 (6-57) | 0 | 25 (6-57) | 12 (6-22) | 8 (1-31) | 0 | 7 (5-31) |
| De novo DLBCL by COO | ||||||||
| ABC | 20 | 25 (9-49) | 5 (0-25) | 25 (9-49) | 11 (5-22) | 21 (5-43) | 14 (2-36) | 68 (4-68) |
| GCB | 36 | 33 (19-51) | 8 (2-23) | 39 (23-57) | 8 (6-27) | 35 (20-51) | 18 (7-33) | 24 (8-NA) |
| Unclassified | 13 | 31 (9-61) | 23 (5-54) | 31 (9-61) | 6 (5-NA) | 31 (10-55) | 31 (10-55) | NA |
| Unknown | 15 | 20 (4-48) | 13 (2-41) | 20 (4-48) | 9 (4-16) | 20 (5-42) | 13 (2-35) | NA |
| De novo DLBCL by gene classifier | ||||||||
| Positive | 32 | 44 (26-62) | 16 (5-33) | 50 (32-68) | 27 (7-47) | 52 (33-68) | 29 (13-47) | 31 (20-NA) |
| Negative | 37 | 19 (8-35) | 5 (1-18) | 19 (8-35) | 7 (6-9) | 12 (4-25) | 9 (2-21) | 33 (4-NA) |
| Unknown | 15 | 20 (4-48) | 13 (2-41) | 20 (4-48) | 9 (4-16) | 20 (5-42) | 13 (2-35) | NA |
| DLBCL type . | n . | ORR (%, 95% CI) . | CR (%, 95% CI) . | DCR (%, 95% CI) . | mPFS (weeks, 95% CI) . | 6-mo PFS (%, 95% CI) . | 12-mo PFS (%, 95% CI) . | mDOR (weeks, 95% CI) . |
|---|---|---|---|---|---|---|---|---|
| All DLBCL | 96 | 28 (19-38) | 9 (4-17) | 30 (21-40) | 9 (7-14) | 25 (17-35) | 15 (8-23) | 31 (18-73) |
| De novo DLBCL | 84 | 29 (19-40) | 11 (5-19) | 31 (21-42) | 8 (6-14) | 28 (19-37) | 17 (9-27) | 33 (20-NA) |
| Transformed lymphoma | 12 | 25 (6-57) | 0 | 25 (6-57) | 12 (6-22) | 8 (1-31) | 0 | 7 (5-31) |
| De novo DLBCL by COO | ||||||||
| ABC | 20 | 25 (9-49) | 5 (0-25) | 25 (9-49) | 11 (5-22) | 21 (5-43) | 14 (2-36) | 68 (4-68) |
| GCB | 36 | 33 (19-51) | 8 (2-23) | 39 (23-57) | 8 (6-27) | 35 (20-51) | 18 (7-33) | 24 (8-NA) |
| Unclassified | 13 | 31 (9-61) | 23 (5-54) | 31 (9-61) | 6 (5-NA) | 31 (10-55) | 31 (10-55) | NA |
| Unknown | 15 | 20 (4-48) | 13 (2-41) | 20 (4-48) | 9 (4-16) | 20 (5-42) | 13 (2-35) | NA |
| De novo DLBCL by gene classifier | ||||||||
| Positive | 32 | 44 (26-62) | 16 (5-33) | 50 (32-68) | 27 (7-47) | 52 (33-68) | 29 (13-47) | 31 (20-NA) |
| Negative | 37 | 19 (8-35) | 5 (1-18) | 19 (8-35) | 7 (6-9) | 12 (4-25) | 9 (2-21) | 33 (4-NA) |
| Unknown | 15 | 20 (4-48) | 13 (2-41) | 20 (4-48) | 9 (4-16) | 20 (5-42) | 13 (2-35) | NA |
Per investigator assessment by revised 2007 International Working Group criteria. Data cutoff 5 April 2018.
CI, confidence interval; DCR; disease control rate; mDOR, median duration of response; mPFS, median progression-free survival; NA, not available; PFS, progression-free survival; TME, tumor microenvironment.